Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Oil slips as Saudi Arabia offers more crude via Oman
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
Pfizer (PFE) Tops Q2 EPS by 9c, Beats on Revenue; Offers FY26 EPS Guidance
August 4, 2026 6:47 AM EDTPfizer (NYSE: PFE) reported Q2 EPS of $0.77, $0.09 better than the analyst estimate of $0.68. Revenue for the quarter came in at $15.03 billion versus the consensus estimate of $14.42 billion.
GUIDANCE:
Pfizer sees FY2026 EPS of $2.80-$3.00, versus the consensus of $2.95.
For earnings history and earnings-related data on Pfizer (PFE) click here.
... More